Statins and Cardiomyocyte Metabolism, Friend or Foe?

Area of Science:

• Cardiology
• Pharmacology
• Biochemistry

Background:

• Statins are primary lipid-lowering drugs inhibiting HMG-CoA reductase, crucial for cholesterol synthesis.
• They significantly decrease cardiovascular morbidity and mortality.
• Musculoskeletal symptoms affect 7-29% of statin users, with mechanisms increasingly understood, yet cardiac effects remain less clear.

Purpose of the Study:

• To review the adverse and beneficial effects of statins on cardiac muscle function.
• To explore differences in statin mechanisms and side effects between cardiac and skeletal muscle.
• To provide insights for personalized statin therapy.

Main Methods:

• Literature review of statin effects on cardiac and skeletal muscle.
• Analysis of mechanisms underlying both beneficial and adverse effects.
• Clinical presentation of statin-induced myopathies and cardiac impacts.

Main Results:

• Statins offer pleiotropic cardioprotective effects (reduced hypertrophy, fibrosis, infarct size) independent of cholesterol lowering.
• Adverse effects in muscle appear linked to altered cardiomyocyte metabolism.
• Distinct clinical presentations and mechanisms exist for cardiac versus skeletal muscle involvement.

Conclusions:

• Statins have dual effects on the heart: beneficial pleiotropic actions and potential adverse metabolic impacts.
• Understanding differential effects on cardiac and skeletal muscle is key.
• Personalized treatment strategies can be developed based on these insights.